Compare CMCO & OABI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CMCO | OABI |
|---|---|---|
| Founded | 1875 | 2012 |
| Country | United States | United States |
| Employees | N/A | 89 |
| Industry | Construction/Ag Equipment/Trucks | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 417.1M | 391.4M |
| IPO Year | 2002 | N/A |
| Metric | CMCO | OABI |
|---|---|---|
| Price | $14.46 | $2.09 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | ★ $21.00 | $4.50 |
| AVG Volume (30 Days) | 580.9K | ★ 646.1K |
| Earning Date | 05-27-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.90% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $936,240,000.00 | N/A |
| Revenue This Year | $19.73 | $52.42 |
| Revenue Next Year | $82.91 | $64.69 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 3.27 | N/A |
| 52 Week Low | $11.99 | $1.32 |
| 52 Week High | $24.40 | $2.79 |
| Indicator | CMCO | OABI |
|---|---|---|
| Relative Strength Index (RSI) | 53.22 | 41.40 |
| Support Level | $13.57 | $1.75 |
| Resistance Level | $15.46 | $2.13 |
| Average True Range (ATR) | 0.75 | 0.16 |
| MACD | 0.12 | -0.04 |
| Stochastic Oscillator | 71.21 | 20.45 |
Columbus McKinnon Corp is a world'wide designer, manufacturer and marketer of intelligent motion solutions for material handling that move the world forward and improve lives by efficiently and ergonomically moving, lifting, positioning and securing materials. Key products include hoists, crane components, precision conveyor systems, rigging tools, light rail workstations and digital power and motion control systems. These are relevant, professional-grade solutions that solve its customers critical material handling requirements.The Company has one operating and reportable segment. It has presence in United State, Germany, Europe, Middle East, and Africa (Excluding Germany), Canada, Asia Pacific, and Latin America. It has majority of sales from United States.
OmniAb Inc licenses discovery research technology to pharmaceutical and biotech companies and academic institutions to enable the discovery of next-generation therapeutics. Its technology platform creates and screens diverse antibody repertoires and is designed to quickly identify optimal antibodies and other target-binding proteins for its partners' drug development efforts. At the heart of the OmniAb platform is what it calls Biological Intelligence, which powers the immune systems of proprietary, engineered transgenic animals to create optimized antibody candidates for human therapeutics.